ACIP Presentation Slides: September 29, 2021 Meeting

Note: These files are not yet 508

Slides will be added as they become available.

September 29, 2021

Welcome & Introductions

• Introduction
  Dr. G Lee
  Dr. M Wharton

Tick-borne Encephalitis (TBE) Vaccine

• Introduction; Immunogenicity and safety of TBE vaccine; Summary and next steps pdf icon[56 pages]
  Dr. K Poehling; Dr. S Hills

Zoster Vaccines

• Introduction pdf icon[10 pages]
  Dr. C Kotton
• Economics of vaccinating immunocompromised 19–49-year-old adults against herpes zoster in the US pdf icon[17 pages]
  Dr. I Ortega-Sanchez
• Preliminary EtR regarding use of RZV in immunocompromised adults and next steps pdf icon[79 pages]
  Dr. T Anderson

Pneumococcal Vaccines

• Introduction pdf icon[17 pages]
  Dr. K Poehling
  
• Summary of economic models assessing pneumococcal vaccines in US adults pdf icon[30 pages]
  Dr. A Leidner
• EtR on risk-based use of PCV15 and PCV20 in adults; Considerations for use of PCV15 and PCV20 in adults and next steps pdf icon[101 pages]
  Dr. M Kobayashi

Hepatitis B Vaccines

• Introduction pdf icon[4 pages]
  Dr. K Ault
  
• HepB-CpG postmarketing surveillance study pdf icon[23 pages]
  Dr. K Bruxvoort
• Universal adult HepB: EtR pdf icon[81 pages]
  Dr. M Doshani

Orthopoxviruses Vaccines

• Introduction pdf icon[7 pages]
  Dr. P Sanchez
  
• Background information to interpret GRADE tables and Evidence to Recommendations frameworks about JYNNEOS® pdf icon[25 pages]
  Dr. A Rao
• Evidence to Recommendations Frameworks for Use of JYNNEOS® pdf icon[89 pages]
  Dr. A Rao